Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era
Simone Pecetta, Oretta Finco, Anja Seubert
Seminars in Immunology (2020) Vol. 50, pp. 101427-101427
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 705
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
Kyle P. Martin, Christine Grimaldi, Rolf Grempler, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 36
Stopping epidemics when and where they occur
Els Torreele, Michel D. Kazatchkine, Joanne Liu, et al.
The Lancet (2023) Vol. 401, Iss. 10374, pp. 324-328
Open Access | Times Cited: 19
Monoclonal antibody applications in travel medicine
Hanna K. de Jong, Martin P. Grobusch
Tropical Diseases Travel Medicine and Vaccines (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Continuous multi‐column capture of monoclonal antibodies with convective diffusive membrane adsorbers
Fabian Schmitz, Elias Knöchelmann, Thomas Kruse, et al.
Biotechnology and Bioengineering (2024) Vol. 121, Iss. 6, pp. 1859-1875
Open Access | Times Cited: 5
Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products
Brian D. Kelley, Pam De Moor, Kristen Douglas, et al.
Current Opinion in Biotechnology (2022) Vol. 78, pp. 102798-102798
Open Access | Times Cited: 25
Upstream cell culture process characterization and in-process control strategy development at pandemic speed
Jianlin Xu, Jianfa Ou, Kyle P. McHugh, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises
Natesh Singh, Bruno O. Villoutreix
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 2537-2548
Open Access | Times Cited: 28
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand
Nicola Zambrano, Guendalina Froechlich, Dejan Lazarević, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1325-1325
Open Access | Times Cited: 20
SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
Tianyi Qiu, Lu Zhang, Zikun Chen, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. W1, pp. W528-W534
Open Access | Times Cited: 11
Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality
Tapan K. Das, Alavattam Sreedhara, James D. Colandene, et al.
Journal of Pharmaceutical Sciences (2021) Vol. 111, Iss. 4, pp. 868-886
Closed Access | Times Cited: 22
High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies
Sayantap Datta, Mohammad Atiqur Rahman, Saisudha Koka, et al.
Cells (2024) Vol. 13, Iss. 23, pp. 1946-1946
Open Access | Times Cited: 2
Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools
María Antonela Zígolo, Matías Rivero Goytia, Hugo Ramiro Poma, et al.
The Science of The Total Environment (2021) Vol. 781, pp. 146400-146400
Open Access | Times Cited: 18
Nanotheranostics: Platforms, Current Applications, and Mechanisms of Targeting in Breast and Prostate Cancers
Paul A. Akpa, Ikechukwu Emmanuel Peter, Akachukwu Marytheresa Onwuka, et al.
Journal of Nanotheranostics (2023) Vol. 4, Iss. 3, pp. 346-383
Open Access | Times Cited: 7
Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection
Evi Struble, Haruhiko Murata, Takashi Komatsu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8728-8728
Open Access | Times Cited: 15
Plague Prevention and Therapy: Perspectives on Current and Future Strategies
Raysa Rosario-Acevedo, Sergei S. Biryukov, Joel A. Bozue, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1421-1421
Open Access | Times Cited: 13
Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
Jacek Plichta, Piotr Kuna, Michał Panek
COVID (2022) Vol. 2, Iss. 5, pp. 599-620
Open Access | Times Cited: 9
Novel approaches for bacterial toxin neutralization; current advances and future perspectives
Mohammad Doroudian, Mohamad Afshar Ardalan, Mehdi Beheshti, et al.
QJM (2024)
Closed Access | Times Cited: 1
A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
Syed Mohammed Basheeruddin Asdaq, Syed Imam Rabbani, Meshary Alkahtani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11953-11953
Open Access | Times Cited: 11
A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, et al.
Gates Open Research (2021) Vol. 5, pp. 117-117
Open Access | Times Cited: 10
CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
Jilly F. Evans, Kseniya Obraztsova, Susan M. Lin, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2233-2233
Open Access | Times Cited: 9
Vector Strategies to Actualize B Cell–Based Gene Therapies
Amanda Jeske, Paul Boucher, David T. Curiel, et al.
The Journal of Immunology (2021) Vol. 207, Iss. 3, pp. 755-764
Open Access | Times Cited: 9
Accelerated cell culture process development and characterization for cilgavimab/tixagevimab (AZD7442) for the prevention and treatment of COVID‐19
Michael W. Handlogten, Stefanie Bosley, Sarah Dunn, et al.
Biotechnology and Bioengineering (2023)
Closed Access | Times Cited: 3
Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis
Justin Chin, Ya‐Qun Zhou, Chijen L Chen, et al.
Cureus (2021)
Open Access | Times Cited: 7
Using vaccines to harness the immune system and fight drugs of abuse
Leah Shaffer
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 52
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top